[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05039866":3,"trial-entities:NCT05039866":170,"trial-summary:NCT05039866":173},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":21,"study_type":29,"primary_purpose":30,"phases":31,"enrollment_info":32,"interventions":35,"primary_outcomes":41,"secondary_outcomes":46,"sex":47,"minimum_age":48,"maximum_age":30,"healthy_volunteers":15,"eligibility_criteria":49,"std_ages":55,"locations":58,"central_contacts":162,"overall_officials":163,"references":168,"see_also_links":169},"NCT05039866","ST-920-LT01","Long-Term Follow-up of Subjects Who Were Treated With ST-920","Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2\u002F6 Human Alpha Galactosidase A Gene Therapy","ENROLLING_BY_INVITATION","2039-03","2025-05","2025-05-25","2021-08-16","Sangamo Therapeutics","INDUSTRY",false,"Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.","Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with ST-920 in the clinical study ST-920-201. All subjects dosed in the study who completed at least 52 weeks post-infusion follow-up in their primary protocol will be offered to participate. Subjects who enroll will be monitored for a total of up to 5 years following ST-920 infusion.",[19,20],"Fabry Disease","Fabry Disease, Cardiac Variant",[19,22,23,24,25,26,27,28],"Gene Therapy","ST-920","Rare","Genetic","DNA","Sangamo","Long Term","OBSERVATIONAL",null,[],{"count":33,"type":34},48,"ESTIMATED",[36],{"type":37,"name":23,"description":38,"armGroupLabels":39},"BIOLOGICAL","No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.",[40],"Subjects who received ST-920",[42],{"measure":43,"description":44,"timeFrame":45},"To evaluate long-term safety of ST-920","To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)","4 years",[],"ALL","18 Years",{"inclusion":50,"exclusion":53,"raw_text":54},[51,52],"Subjects who received ST-920 therapy in a separate parent trial","Subjects who have consented to participate in this LTFU study.",[],"Inclusion Criteria:\n\n* Subjects who received ST-920 therapy in a separate parent trial\n* Subjects who have consented to participate in this LTFU study.\n\nExclusion Criteria:\n\n-This study has no exclusion criteria",[56,57],"ADULT","OLDER_ADULT",[59,68,76,84,92,100,107,115,123,132,141,148,156],{"facility":60,"city":61,"state":62,"zip":63,"country":64,"geoPoint":65},"University of California, Irvine","Irvine","California","92697","United States",{"lat":66,"lon":67},33.66946,-117.82311,{"facility":69,"city":70,"state":71,"zip":72,"country":64,"geoPoint":73},"University of South Florida","Tampa","Florida","33620",{"lat":74,"lon":75},27.94752,-82.45843,{"facility":77,"city":78,"state":79,"zip":80,"country":64,"geoPoint":81},"Emory University School of Medicine","Atlanta","Georgia","30322",{"lat":82,"lon":83},33.749,-84.38798,{"facility":85,"city":86,"state":87,"zip":88,"country":64,"geoPoint":89},"University of Iowa Hospital and Clinics","Iowa City","Iowa","52242",{"lat":90,"lon":91},41.66113,-91.53017,{"facility":93,"city":94,"state":95,"zip":96,"country":64,"geoPoint":97},"University of Minnesota Medical Center","Minneapolis","Minnesota","55455",{"lat":98,"lon":99},44.97997,-93.26384,{"facility":101,"city":102,"state":102,"zip":103,"country":64,"geoPoint":104},"Mt. Sinai Hospital","New York","10029",{"lat":105,"lon":106},40.71427,-74.00597,{"facility":108,"city":109,"state":110,"zip":111,"country":64,"geoPoint":112},"Cincinnati Children's Hospital Medical Center","Cincinnati","Ohio","45229",{"lat":113,"lon":114},39.12711,-84.51439,{"facility":116,"city":117,"state":118,"zip":119,"country":64,"geoPoint":120},"Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)","Fairfax","Virginia","22030",{"lat":121,"lon":122},38.84622,-77.30637,{"facility":124,"city":125,"state":126,"zip":127,"country":128,"geoPoint":129},"The Royal Melbourne Hospital","Parkville","Victoria","3050","Australia",{"lat":130,"lon":131},-37.78333,144.95,{"facility":133,"city":134,"state":135,"zip":136,"country":137,"geoPoint":138},"M.A.G.I.C. Clinic Ltd.","Calgary","Alberta","T2E 7Z4","Canada",{"lat":139,"lon":140},51.05011,-114.08529,{"facility":142,"city":143,"country":144,"geoPoint":145},"University Hospital of Würzburg","Würzburg","Germany",{"lat":146,"lon":147},49.79391,9.95121,{"facility":149,"city":150,"zip":151,"country":152,"geoPoint":153},"Addenbrooke's Hospital","Cambridge","CB2 0QQ","United Kingdom",{"lat":154,"lon":155},52.2,0.11667,{"facility":157,"city":158,"country":152,"geoPoint":159},"Royal Free Hospital","London",{"lat":160,"lon":161},51.50853,-0.12574,[],[164],{"name":165,"affiliation":166,"role":167},"Medical Monitor","Sangamo Therapeutics, Inc.","STUDY_DIRECTOR",[],[],{"nct_id":4,"conditions":171,"biomarkers":172},[19],[],{"nct_id":4,"found":15,"summary":30,"prompt_version":30}]